H
Hua Medicine
HKEX:2552
Hua Medicine
HKEX:2552
Price:
1.59 HKD
-1.24%
Market Closed
Updated:
May 4, 2024
Section:
Relative Value
The Relative Value of one Hua Medicine stock under the Base Case scenario is 1.75 HKD. Compared to the current market price of 1.59 HKD, Hua Medicine is Undervalued by 9%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Relative Value
Base Case
1.75
HKD
Undervaluation 9%
H
Valuation Multiples
Multiples Across Competitors
Competitors Multiples
Hua Medicine Competitors
Hua Medicine Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
H
|
Hua Medicine
HKEX:2552
|
1.5B HKD | 81.3 | -7 | -5.1 | -4.4 | |
| JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | 4 211 733 | -5 347 888.9 | -5 459 134.4 | -5 046 864.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
697.9B USD | 20.4 | 133.2 | 60.2 | 69.1 | |
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 578.3 | -15 783.5 | 3 846.3 | 17 702.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
3.8T DKK | 16.3 | 45.2 | 33 | 36 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
357.8B USD | 4.4 | 8.8 | 11.8 | 15.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
323.8B USD | 5.3 | 140.4 | 33.4 | 53 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
186.8B GBP | 5.1 | 39.4 | 140.7 | 225.6 | |
| CH |
|
Novartis AG
SIX:NOVN
|
179.8B CHF | 4.3 | 13.4 | 9.8 | 16.2 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
173.2B CHF | 3 | 15.1 | 8.6 | 10.2 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
155.7B USD | 2.7 | 73.5 | 11 | 16.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
